Bristol-Myers business development head Biondi departs

百时美施贵宝战略和业务发展主管离职

2019-12-13 11:06:10 YAHOO!FINANCE

本文共322个字,阅读需1分钟

Bristol-Myers Squibb Co's head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday. A Bristol-Myers spokeswoman said Biondi decided to leave to pursue an external opportunity and that the U.S. drugmaker is actively searching for his successor. Biondi could not immediately be reached for comment. Biondi joined Bristol-Myers in 2002 and had been in charge of business development, helping the company pursue strategic partnerships and deals, since 2015. Bristol-Myers announced the Celgene acquisition last January and the deal closed on Nov. 28. In June, the company had said Biondi would be part of the combined company's leadership.
百时美施贵宝公司( Bristol-Myers Squibb Co .)的战略和业务发展主管保罗·比昂迪( Paul Biondi )在完成对生物技术公司新基(Celgene) Corp 价值740亿美元的收购时于上月离职。 百时美施贵宝发言人说, Biondi 决定离开,寻求外部机会,美国制药商正积极寻找他的继任者。无法立即联系 Biondi 征求意见。 Biondi 于2002年加入百时美(Bristol-Myers),自2015年以来一直负责业务发展,帮助公司寻求战略合作伙伴和交易。 去年1月,百时美施贵宝宣布收购新基(Celgene),交易于11月28日结束。今年6月,该公司曾表示, Biondi 将是合并后公司领导层的一部分。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文